Global Retirement Partners LLC Sells 2,872 Shares of Genmab A/S (NASDAQ:GMAB)

Global Retirement Partners LLC lessened its position in shares of Genmab A/S (NASDAQ:GMAB) by 58.8% in the 4th quarter, HoldingsChannel reports. The fund owned 2,014 shares of the company’s stock after selling 2,872 shares during the period. Global Retirement Partners LLC’s holdings in Genmab A/S were worth $42,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Two Sigma Advisers LP increased its position in shares of Genmab A/S by 84.1% during the third quarter. Two Sigma Advisers LP now owns 615,100 shares of the company’s stock worth $14,996,000 after purchasing an additional 280,900 shares in the last quarter. FMR LLC grew its stake in Genmab A/S by 13.5% during the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after buying an additional 33,076 shares during the last quarter. Oppenheimer Asset Management Inc. increased its position in Genmab A/S by 6.5% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 232,243 shares of the company’s stock valued at $5,662,000 after buying an additional 14,165 shares in the last quarter. Natixis Advisors LLC raised its stake in Genmab A/S by 29.8% in the third quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock valued at $5,036,000 after buying an additional 47,437 shares during the last quarter. Finally, ABC Arbitrage SA acquired a new stake in Genmab A/S in the fourth quarter worth about $3,692,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Price Performance

NASDAQ:GMAB opened at $22.67 on Friday. The company’s fifty day moving average price is $20.98 and its 200-day moving average price is $22.78. Genmab A/S has a 1-year low of $18.64 and a 1-year high of $31.88. The firm has a market capitalization of $15.00 billion, a P/E ratio of 13.03, a PEG ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. Equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on GMAB shares. BNP Paribas upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a research report on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $42.17.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.